US-based genomics technology developer Helix has received $50m series C funding from investors including medical research group Mayo Clinic.
Venture capital firms DFJ Growth and Kleiner Perkins, Singaporean state-owned investment firm Temasek and private equity firm Warburg Pincus filled out the round.
Helix provides a personal genomics products and services platform which helps healthcare providers personalise patient treatments. The funding will be used to improve its offering, in areas including covid-19 testing and viral surveillance.
Mayo Clinic had taken part in a $200m series B round for the company in 2018 that was led by DFJ and backed by genetics analysis technology provider Illumina, Temasek, Kleiner Perkins predecessor Kleiner Perkins Caufield & Byers, Sutter Hill Ventures and Warburg Pincus.
Shortly after its launch in 2015, Helix secured in excess of $100m in series A funding from Illumina, Mayo Clinic, Warburg Pincus and Sutter Hill Ventures.
